CDA | Evidence Driven
CDA | Evidence Driven

durvalumab

Details

Generic Name:
durvalumab
Project Status:
Pending
Therapeutic Area:
resectable non-small cell lung cancer (NSCLC)
Manufacturer:
AstraZeneca Canada Inc.
Call for patient/clinician input open:
Brand Name:
Imfinzi
Project Line:
Reimbursement Review
Project Number:
PC0372-000
Call for patient/clinician input closed:
Tumour Type:
Lung
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Imfinzi (durvalumab) in combination with chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy after surgery, is indicated for the treatment of patients with resectable (tumours ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​Anticipated indication: Imfinzi (durvalumab) in combination with chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy after surgery, is indicated for the treatment of patients with resectable (tumours ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : May 30, 2024